ArticleCell host & microbe2010
Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease.
Article in Cell host & microbe, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 212 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
212 citing papers in PubMed, 2 syntheses or guidelines pooled it, 339 citations in OpenAlex.
- Predictive symptoms and signs of severe dengue disease for patients with dengue fever: a meta-analysis.BioMed research international · 2014Pooled it
- Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells.Proceedings of the National Academy of Sciences of the United States of America · 2013Pooled it
- Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials.PLoS neglected tropical diseases · 2016Trial
- Trial
- Kinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengue.PLoS neglected tropical diseases · 2011Trial
- Oral lipid prodrug V2043 (1-Antimicrobial agents and chemotherapy · 2026Article
- A Zika virus vaccine with E protein fusion loop mutations protects via CD8Nature microbiology · 2026Article
- Multiple, but not isolated, yellow fever virus-associated orthoflavivirus immune histories drive antibody-dependent enhancement of Zika and dengue viruses.medRxiv : the preprint server for health sciences · 2026Article
- Uterine natural killer cell-mediated immune imbalance impairs uterine vascular remodeling and contributes to adverse pregnancy outcomes in dengue virus-infected mice.Microbiology spectrum · 2026Article
- Strain-specific pathogenicity and antibody-dependent enhancement of dengue virus infection inThe Journal of general virology · 2026Article
- Dengue Dilemma: Navigating Cross-Reactivity and Immune Challenges.Current topics in microbiology and immunology · 2026Review
- Virus-like Particles and Spectral Flow Cytometry for Identification of Dengue Virus-Specific B Cells in Mice and Humans.Viruses · 2025Article
- Article
- Meeting report: 38th international conference on antiviral research in Las Vegas, United States of America, March 17-21, 2025.Antiviral research · 2025Article
- A lethal DENV-2 wild-type mouse model for mutagenesis investigations.BMC biology · 2025Article
- Cross-genotype immunogenicity and antibody-dependent enhancement of KD-382 dengue vaccine in flavivirus-naïve adults.NPJ vaccines · 2025Article
- Anti-pA137R antibodies exacerbate the pathogenicity of African swine fever virus in pigs.Journal of virology · 2025Article
- Zika but not Dengue virus infection limits NF-κB activity in human monocyte-derived dendritic cells and suppresses their ability to activate T cells.Nature communications · 2025Article
- Harnessing defective interfering particles and lipid nanoparticles for effective delivery of an anti-dengue virus RNA therapy.Molecular therapy. Nucleic acids · 2025Article
- Predicting the infecting dengue serotype from antibody titre data using machine learning.PLoS computational biology · 2024Article
152 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Dengue virus (DENV) causes disease ranging from dengue fever (DF), a self-limited febrile illness, to the potentially lethal dengue hemorrhagic fever and dengue shock syndrome (DHF/DSS). DHF/DSS usually occurs in patients who have acquired DENV-reactive antibodies prior to infection, either from a previous infection with a heterologous DENV serotype or from an immune mother. Hence, it has been hypothesized that subneutralizing levels of antibodies exacerbate disease, a phenomenon termed antibody-dependent enhancement (ADE). However, given the lack of suitable animal models for DENV infection, the mechanism of ADE and its contribution to pathology remain elusive. Here we demonstrate in mice that DENV-specific antibodies can sufficiently increase severity of disease so that a mostly nonlethal illness becomes a fatal disease resembling human DHF/DSS. Antibodies promote massive infection of liver sinusoidal endothelial cells (LSECs), resulting in increased systemic levels of virus. Thus, a subprotective humoral response may, under some circumstances, have pathological consequences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.